We reviewed translations of early Japanese articles on Kawasaki syndrome, polyarteritis nodosa, and fatal infantile periarteritis nodosa. JCB was a member of a research team that undertook extensive interviews in Japan with key figures involved in the recognition of the syndrome as a distinct clinical entity. We reviewed relevant abstracts from the seven international symposia held since 1984. We reviewed selected publications from the PubMed database identified by searches with the
SeminarKawasaki syndrome
Introduction
Tomisaku Kawasaki saw his first case of an unusual illness with rash and fever in a 4-year-old child at the Red Cross Hospital in Tokyo, Japan, in January, 1961. During the next 6 years, he saw 50 similar patients, and he published first reports on the disorder in Japanese in 19671 and in English in 1974.2 An English translation of the 1967 paper became available only in 2002.3 Reports from Japan from the 1950s described similar patients.4 However, no published reports could be found of Japanese patients with the symptom complex of Kawasaki syndrome before the 1950s. To address the question of when the syndrome first appeared in Japan, researchers reviewed the records of 7618 children admitted to the Tokyo University Hospital between 1940 and 1954 for 15 different rash/fever diagnoses. They found 144 patients with one of these rash/fever diagnoses, of whom only five met all the clinical criteria for Kawasaki syndrome.5 None of these patients was seen before 1950. That study coupled with other historical inquiry suggests that cases of the disorder were not seen in Japan before the 1950s.
The most important issue about the syndrome in the 1960s in Japan was whether the illness described by Kawasaki was connected to subsequent cardiac complications noted in some cases. Noboru Tanaka, a pathologist, and Takajiro Yamamoto, a paediatrician, disputed Kawasaki's early assertion that the syndrome had no long-term sequelae.4 The controversy was resolved in 1970 when a nationwide survey in Japan identified ten autopsy cases of children who had died from complications of coronary-artery aneurysms after Kawasaki syndrome.6 By the time Kawasaki's paper was published in English in 1974, the link between the syndrome and coronary-artery vasculitis was well established.
Kawasaki syndrome was independently recognised as a new and distinct disorder in the early 1970s by Melish and Hicks at the University of Hawaii.4, 7, 8 Different features of the same complex of signs and symptoms were emphasised by these investigators, who focused on the urethritis and sterile pyuria and the inflammation of small and large joints that accompanied the illness in almost a third of patients. In 1973, Larson and Landing retrospectively diagnosed a 1971 autopsy case as Kawasaki syndrome. The similarity between fatal Kawasaki syndrome and infantile polyarteritis nodosa was apparent to these pathologists, as it had been to Tanaka earlier.9
Case reports of infantile polyarteritis nodosa from western Europe extend back to the 19th century.10 What remains unknown is the reason for the simultaneous recognition of fatal and non-fatal Kawasaki syndrome around the world in the 1960s and 1970s.10 Several hypotheses have been proposed. The syndrome could have newly emerged in Japan and emanated elsewhere through Hawaii, where the disease is most prevalent among Asian-American children. Alternatively, Kawasaki syndrome and infantile polyarteritis nodosa could be part of the continuum of the same disease, and clinically mild Kawasaki syndrome masqueraded as other diseases such as measles or scarlet fever before the advent of vaccines and antibiotics.
Section snippets
Diagnosis
Kawasaki syndrome is self-limited; the signs and symptoms evolve over the first 10 days of illness then gradually resolve spontaneously in most children, even in the absence of specific therapy (figure 1). Coronary-artery aneurysms develop in 20–25% of cases; their development is clinically silent in most cases and may be recognised only years later at the time of sudden death or myocardial infarction.11, 12 Treatment with high-dose intravenous immunoglobulin (IVIG) within the first 10 days of
Epidemiology
Kawasaki syndrome has been reported in all racial and ethnic groups and across the entire paediatric age range, although in most series 85% of patients are younger than 5 years. Patients younger than 6 months or older than 8 years are encountered infrequently but might be at increased risk of coronary-artery aneurysms.28, 29, 30, 31 The reported annual incidence rates of the syndrome per 100 000 children under 5 years of age by country range from 3 in South America to 134 in Japan, although the
Aetiology
The cause of Kawasaki syndrome remains unknown, although an infectious agent is suspected in view of the following evidence. There is a seasonal peak in the winter and spring months in most geographical areas, and geographically focal epidemics occurred in the 1970s and 1980s. The peak incidence in the toddler age-group with only rare cases in infants under 3 months of age and in adults suggests a role for transplacental antibodies conferring protection and development of protective immunity as
Pathology
Our understanding of the pathological changes of the vasculitis of Kawasaki syndrome has been impeded by the paucity of clinical material available for study. The low mortality rate coupled with primary involvement of medium-sized extraparenchymal muscular arteries, particularly the coronary arteries, which cannot be sampled during life, has precluded a comprehensive understanding of how the pathological changes in the vessel wall evolve. Although both Kawasaki syndrome and adult-type
Immunopathogenesis
Activation of the immune system is a central feature of Kawasaki syndrome, and concentrations of many proinflammatory cytokines and chemokines, including tumour necrosis factor α (TNFα), interleukins 1, 6, and 8, are higher than normal during the acute phase of the disease.55, 56, 57, 58, 59, 60 Activated monocytes/macrophages seem to have an important role in Kawasaki syndrome.61, 62, 63 These cells have been found in the vessel walls of patients who died63 and in skin biopsy samples from
Initial treatment
In 1983, Japanese investigators reported that children with Kawasaki syndrome treated with IVIG had faster resolution of fever and developed fewer coronary-artery abnormalities than historical controls.68 A multicentre, open-label, randomised trial in the USA showed that children treated with IVIG and high-dose aspirin had significantly faster resolution of fever and other inflammatory markers than children treated with high-dose aspirin alone.13 Moreover, the frequency of coronary-artery
Genetic influence
A genetic influence on disease susceptibility is suspected because Kawasaki syndrome is over-represented among Asian and Asian-American populations. Furthermore, the frequency is higher than in the general population among siblings of an index case. In Japan, the relative risk for siblings of developing the syndrome is 10.93 No sibling statistics are available for the USA or western Europe. The frequency of the disorder was two times higher than predicted in parents of children with Kawasaki
Cardiovascular complications and long-term sequelae
Large series of patients from Japan and North America have established the following features of the natural history of Kawasaki syndrome. Coronary-artery aneurysms occur as a sequela of the vasculitis in 20–25% of untreated children.111 Other cardiovascular complications of the syndrome include myocarditis, pericarditis with effusion, and valvulitis, which occurs in about 1% of patients and most commonly involves the mitral valve.112 Echocardiography is a sensitive and reliable method to
Obstacles to success
Why in the 37 years since the first description of Kawasaki syndrome as a unique clinical entity has there not been better progress in elucidation of the nature of this disease? Some impediments may include the following. The lack of a clear aetiological agent has made the classification and thus the sources of research funding unclear. Is this disease the responsibility of agencies or institutes that fund cardiovascular research, rheumatological research, or infectious diseases? To obtain
Conclusion
Although great strides have been made in the treatment of Kawasaki syndrome and in our understanding of the natural history of the disease, major questions remain unanswered. The extent to which the syndrome may eventually contribute to the burden of adult cardiovascular disease is of growing concern. Until a diagnostic test is devised, children will continue to be misdiagnosed and suffer preventable morbidity and mortality. Priorities for research should focus on devising a diagnostic test so
Search strategy and selection criteria
References (152)
- et al.
Adult coronary artery disease probably due to childhood Kawasaki disease
Lancet
(1992) - et al.
Sequelae of Kawasaki disease in adolescents and young adults
J Am Coll Cardiol
(1996) - et al.
Clinical and epidemiological characteristics of patients referred for evaluation of possible Kawasaki disease
J Pediatr
(1991) - et al.
Incomplete Kawasaki disease with coronary artery involvement
J Pediatr
(1987) - et al.
The clinical spectrum of Kawasaki syndrome in infants less than six months of age
J Pediatr
(1986) - et al.
Kawasaki disease in infants less than one year of age
J Pediatr
(1995) - et al.
Kawasaki disease in older children and adolescents
J Pediatr
(2000) - et al.
Kawasaki syndrome: association with the application of rug shampoo
Lancet
(1982) - et al.
Association of rug shampooing and Kawasaki disease
J Pediatr
(1991) - et al.
Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease
J Pediatr
(2002)
Vascular endothelial growth factor in acute Kawasaki disease
Am J Cardiol
Peripheral blood monocyte/macrophage and serum tumor necrosis factor in Kawasaki disease
Clin Immunol Immunopathol
Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon gamma in Kawasaki disease involved coronary artery lesions
Clin Immunol Immunopathol
High-dose intravenous gamma globulin for Kawasaki disease
Lancet
Early treatment with intravenous immunoglobulin in patients with Kawasaki disease
J Pediatr
Am J Cardiol
High dose intravenous globulin treatment enhances natural killer cell activity in Kawasaki disease
J Pediatr
Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins
Am J Pathol
Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose
J Pediatr
Kawasaki disease: who is at risk?
J Pediatr
Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids
J Pediatr
Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial
J Pediatr
Immunoglobulin allotypic markers in Kawasaki disease
Pediatrics
[Pediatric acute mucocutaneous lymph node syndrome: clinical observation of 50 cases]
Arerugi (Jpn J Allergy)
A new infantile acute febrile mucocutaneous lymph node syndrome (MCLS) prevailing in Japan
Pediatrics
Translation of Dr Tomisaku Kawasaki's original report of fifty patients in 1967
Pediatr Infect Dis J
Kawasaki disease: a brief history
Pediatrics
Kawasaki disease before Kawasaki at Tokyo University Hospital
Pediatrics
[Clinicopathological conference on 10 fatal cases with acute febrile mucocutaneous lymph node syndrome]. Shonika
Rinsho (Jpn J Pediatr)
Mucocutaneous lymph node syndrome in the US
Pediatr Res
Mucocutaneous lymph node syndrome in the United States
Am J Dis Child
Are infantile periarteritis nodosa with coronary artery involvement and fatal mucocutaneous lymph node syndrome the same? Comparison of 20 patients from North America with patients from Hawaii and Japan
Pediatrics
Rethinking the boundaries of Kawasaki disease
Perspect Biol Med
Treatment of Kawasaki syndrome with intravenous gamma globulin
N Engl J Med
Single infusion of intravenous gamma globulin compared to four daily doses in the treatment of acute Kawasaki syndrome
N Engl J Med
Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria
Pediatrics
Atypical and complicated Kawasaki disease in infants: do we need criteria?
West J Med
Fulfillment of diagnostic criteria in Kawasaki disease
South Med J
Sensitivity of the Kawasaki case definition for detecting coronary artery abnormalities
Pediatr Res
Kawasaki disease and the eye
Pediatr Infect Dis J
Cerebrospinal fluid profile in patients with acute Kawasaki disease
Pediatr Infect Dis J
Elevated gamma-glutamyl transferase concentrations in patients with acute Kawasaki disease
Pediatr Infect Dis J
The differentiation of classic Kawasaki disease, atypical Kawasaki disease, and acute adenoviral infection: use of clinical features and a rapid direct fluorescent antigen test
Arch Pediatr Adolesc Med
Incidence and clinical features of incomplete Kawasaki disease
Acta Paediatr
Ultrasonographic evaluation of cervical lymph nodes in Kawasaki disease
Pediatrics
Kawasaki disease and cervical adenopathy: an update for the otolaryngologist
Arch Otolaryngol
Kawasaki disease in the older child
Pediatrics
Summary and abstracts of the Seventh International Kawasaki Disease Symposium
Pediatr Res
Rising incidence of Kawasaki disease in England: analysis of hospital admission data
BMJ
Kawasaki syndrome hospitalizations in the United States, 1997 and 2000
Pediatrics
Cited by (838)
Multisystem inflammatory syndrome in children: Another COVID-19 sequel
2023, Cardiology in the YoungKawasaki disease in neonates: a case report and literature review
2024, Pediatric Rheumatology